AR080982A1 - Derivados de quinoxalina - Google Patents

Derivados de quinoxalina

Info

Publication number
AR080982A1
AR080982A1 ARP110101476A AR080982A1 AR 080982 A1 AR080982 A1 AR 080982A1 AR P110101476 A ARP110101476 A AR P110101476A AR 080982 A1 AR080982 A1 AR 080982A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
nr14r15
alkoxy
haloalkyl
Prior art date
Application number
Other languages
English (en)
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of AR080982A1 publication Critical patent/AR080982A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Composiciones farmacéuticas que comprenden dichos compuestos, a procesos para la preparacion de dichos compuestos y al uso de dichos compuestos en el tratamiento de enfermedades, por ejemplo, cáncer. Reivindicacion 1: Un compuesto de la formula (1) incluyendo cualquier forma tautomérica o estereoquímicamente isomérica de ellos, en donde n representa un numero entero igual a 0, 1, 2, 3 o 4; R1 representa hidrogeno, alquilo C1-6, alquenilo C2-4, hidroxialquilo C1-6, haloalquilo C1-6, hidroxihaloalquilo C1-6, cianoalquilo C1-4, alcoxi C1-6-alquilo C1-6, en donde cada alquilo C1-6 puede estar opcionalmente sustituido con uno o dos grupos hidroxilo, alquilo C1-6 sustituido con -NR4R5, alquilo C1-6 sustituido con -C(=O)-NR4R5, -S(=O)2-alquilo C1-6, -S(=O)2-haloalquilo C1-6, -S(=O)2-NR14R15, alquilo C1-6 sustituido con -S(=O)2-alquilo C1-6, alquilo C1-6 sustituido con -S(=O)2-haloalquilo C1-6, alquilo C1-6 sustituido con -S(=O)2-NR14R15, alquilo C1-6 sustituido con -NH-S(=O)2-alquilo C1-6, alquilo C1-6 sustituido con -NH-S(=O)2-haloalquilo C1-6, alquilo C1-6 sustituido con -NR12-S(=O)2-NR14R15, R6, alquilo C1-6 sustituido con R6, alquilo C1-6 sustituido con -C(=O)-R6, hidroxialquilo C1-6 sustituido con R6, alquilo C1-6 sustituido con -Si(CH3)3, alquilo C1-6 sustituido con -P(=O)(OH)2 o alquilo C1-6 sustituido con -P(=O)(Oalquilo C1-6)2; cada R1a está seleccionado, de modo independiente, de hidrogeno, alquilo C1-4, hidroxialquilo C1-4, alquilo C1-4 sustituido con amino o mono- o di(alquil C1-4)amino o -NH(cicloalquilo C3-8), cianoalquilo C1-4, alcoxi C1-4-alquilo C1-4 y alquilo C1-4 sustituido con uno o varios átomos de fluor; cada R2 está seleccionado, de modo independiente, de hidroxilo, halogeno, ciano, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, alcoxi C1-4, hidroxialquilo C1-4, hidroxialcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4, hidroxihaloalquilo C1-4, hidroxihaloalcoxi C1-4, alcoxi C1-4-alquilo C1-4, haloalcoxi C1-4-alquilo C1-4, alcoxi C1-4-alquilo C1-4, en donde cada alquilo C1-4 puede estar opcionalmente sustituido con uno o dos grupos hidroxilo, hidroxihaloalcoxi C1-4-alquilo C1-4, R13, alquilo C1-4 sustituido con R13, alquilo C1-4 sustituido con -C(=O)-R13, alcoxi C1-4 sustituido con R13, alcoxi C1-4 sustituido con -C(=O)-R13, -C(=O)-R13, alquilo C1-4 sustituido con -NR7R8, alquilo C1-4 sustituido con -C(=O)-NR7R8, alcoxi C1-4 sustituido con -NR7R8, alcoxi C1-4 sustituido con -C(=O)-NR7R8, -NR7R8 y -C(=O)-NR7R8, o cuando dos grupos R2 están unidos a átomos de carbono adyacentes, se pueden tomar juntos para formar un radical de la formula -O-(C(R17)2)p-O-; -X-CH=CH-; o -X-CH=N-; en donde R17 representa hidrogeno o fluor, p representa 1 o 2 y X representa O o S; R3 representa hidroxilo, alcoxi C1-6, hidroxialcoxi C1-6, alcoxi C1-6 sustituido con -NR10R11, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6 opcionalmente sustituido con -O-C(=O)-alquilo C1-6, hidroxialquilo C1-6 opcionalmente sustituido con -O-C(=O)-alquilo C1-6, hidroxialquenilo C2-6, hidroxialquinilo C2-6, hidroxihaloalquilo C1-6, cianoalquilo C1-6, alquilo C1-6 sustituido con carboxilo, alquilo C1-6 sustituido con -C(=O)-alquilo C1-6, alquilo C1-6 sustituido con -C(=O)-O-alquilo C1-6, alquilo C1-6 sustituido con alcoxi C1-6-alquil C1-6-O-C(=O)-, alquilo C1-6 sustituido con alcoxi C1-6-alquil C1-6-C(=O)-, alquilo C1-6 sustituido con -O-C(=O)-alquilo C1-6, alcoxi C1-6-alquilo C1-6, en donde cada alquilo C1-6 puede estar opcionalmente sustituido con uno o dos grupos hidroxilo o con -O-C(=O)-alquilo C1-6, alquenilo C2-6 sustituido con alcoxi C1-6, alquinilo C2-6 sustituido con alcoxi C1-6, alquilo C1-6 sustituido con R9 y opcionalmente sustituido con -O-C(=O)-alquilo C1-6, alquilo C1-6 sustituido con -C(=O)-R9, alquilo C1-6 sustituido con hidroxilo y R9, alquenilo C2-6 sustituido con R9, alquinilo C2-6 sustituido con R9, alquilo C1-6 sustituido con -NR10R11, alquenilo C2-6 sustituido con -NR10R11, alquinilo C2-6 sustituido con -NR10R11, alquilo C1-6 sustituido con hidroxilo y -NR10R11, alquilo C1-6 sustituido con uno o dos halogenos y -NR10R11, -alquil C1-6-C(R12)=N-O-R12, alquilo C1-6 sustituido con -C(=O)-NR10R11, alquilo C1-6 sustituido con -O-C(=O)-NR10R11, -S(=O)2-alquilo C1-6, -S(=O)2-haloalquilo C1-6, -S(=O)2-NR14R15, alquilo C1-6 sustituido con -S(=O)2-alquilo C1-6, alquilo C1-6 sustituido con -S(=O)2-haloalquilo C1-6, alquilo C1-6 sustituido con -S(=O)2-NR14R15, alquilo C1-6 sustituido con -NR12-S(=O)2-alquilo C1-6, alquilo C1-6 sustituido con -NH-S(=O)2-haloalquilo C1-6, alquilo C1-6 sustituido con -NR12-S(=O)2-NR14R15, R13, alquilo C1-6 sustituido con -P(=O)(OH)2 o alquilo C1-6 sustituido con -P(=O)(Oalquilo C1-6)2; R4 y R5 representan cada uno, de modo independiente, hidrogeno, alquilo C1-6, hidroxialquilo C1-6, haloalquilo C1-6, hidroxihaloalquilo C1-6, alcoxi C1-6-alquilo en donde cada alquilo C1-6 puede estar opcionalmente sustituido con uno o dos grupos hidroxilo, -S(=O)2-alquilo C1-6, -S(=O)2-haloalquilo C1-6, -S(=O)2-NR14R15, alquilo C1-6 sustituido con -S(=O)2-alquilo C1-6, alquilo C1-6 sustituido con -S(=O)2-haloalquilo C1-6, alquilo C1-6 sustituido con -S(=O)2-NR14R15, alquilo C1-6 sustituido con -NH-S(=O)2-alquilo C1-6, alquilo C1-6 sustituido con -NH-S(=O)2-haloalquilo C1-6, alquilo C1-6 sustituido con -NH-S(=O)2-NR14R15, R13 o alquilo C1-6 sustituido con R13; R6 representa cicloalquilo C3-8, cicloalquenilo C3-8, fenilo, heterociclilo monocíclico de 4 a 7 miembros que contiene al menos un heteroátomo seleccionado de N, O o S; dicho cicloalquilo C3-8, cicloalquenilo C3-8, fenilo, heterociclilo monocíclico de 4 a 7 miembros, opcionalmente y, de modo independiente, cada uno sustituido con 1, 2, 3, 4 o 5 sustituyentes, estando seleccionado cada sustituyente de modo independiente de ciano, alquilo C1-6, cianoalquilo C1-6, hidroxilo, carboxilo, hidroxialquilo C1-6, halogeno, haloalquilo C1-6, hidroxihaloalquilo C1-6, alcoxi C1-6, alcoxi C1-6-alquilo C1-6, alquil C16-O-C(=O)-, -NR14R15, -C(=O)-NR14R15, alquilo C1-6 sustituido con -NR14R15, alquilo C1-6 sustituido con -C(=O)-NR14R15, -S(=O)2-alquilo C1-6, -S(=O)2- haloalquilo C1-6, -S(=O)2-NR14R15, alquilo C1-6 sustituido con -S(=O)2-alquilo C1-6, alquilo C1-6 sustituido con -S(=O)2-haloalquilo C1-6, alquilo C 1-6 sustituido con -S(=O)2-NR4R15, alquilo C1-6 sustituido con -NH-S(=O)2- alquilo C1-6, alquilo C1-6 sustituido con -NH-S(=O)2-haloalquilo C1-6 o alquilo C1-6 sustituido con -NH-S(=O)2-NR14R15; R7 y R8 representan cada uno, de modo independiente, hidrogeno, alquilo C1-6, hidroxialquilo C1-6, haloalquilo C1-6, hidroxihaloalquilo C1-6 o alcoxi C1-6-alquilo C1-6; R9 representa cicloalquilo C3-8, cicloalquenilo C3-8, fenilo, naftilo o heterociclilo monocíclico o bicíclico de 3 a 12 miembros que contiene al menos un heteroátomo seleccionado de N, O o S, estando dicho cicloalquilo C3-8, cicloalquenilo C3-8, fenilo, naftilo o heterociclilo monocíclico o bicíclico de 3 a 12 miembros opcional e independientemente sustituido con 1, 2, 3, 4 o 5 sustituyentes, estando seleccionado cada sustituyente de modo independiente de =O, alquilo C1-4, hidroxilo, carboxilo, hidroxialquilo C1-4, ciano, cianoalquilo C1-4, alquil C1-4-O-C(=O)-, alquilo C1-4 sustituido con alquil C1-4-O-C(=O)-, alquil C1-4-C(=O)-, alcoxi C1-4-alquilo C1-4, en donde cada alquilo C1-4 puede estar opcionalmente sustituido con uno o dos grupos hidroxilo, halogeno, haloalquilo C1-4, hidroxihaloalquilo C1-4, -NR14R15, -C(=O)-NR14R15, alquilo C1-4 sustituido con -NR14R15, alquilo C1-4 sustituido con -C(=O)-NR14R15, alcoxi C1-4, -S(=O)2-alquilo C1-4, -S(=O)2-haloalquilo C1-4, -S(=O)2-NR14R15, alquilo C1-4 sustituido con -S(=O)2-NR14R15, alquilo C1-4 sustituido con -NH-S(=O)2-alquilo C1-4, alquilo C1-4 sustituido con - NH-S(=O)2-haloalquilo C1-4, alquilo C1-4 sustituido con -NH-S(=O)2-NR14R15, R13, -C(=O)-R13, alquilo C1-4 sustituido con R13, fenilo opcionalmente sustituido con R16, fenilalquilo C1-6, en donde el fenilo está opcionalmente sustituido con R16, un heterociclilo monocíclico aromático de 5 o 6 miembros que contiene al menos un heteroátomo seleccionado de N, O o S en donde dicho heterociclilo está opcionalmente sustituido con R16; o cuando dos de los sustituyentes de R9 están unidos al mismo átomo, se pueden tomar juntos para formar un heterociclilo monocíclico saturado de 4 a 7 miembros que contiene al menos un heteroátomo seleccionado de N, O o S; R10 y R11 representan cada uno, de modo independiente, hidrogeno, carboxilo, alquilo C1-6, cianoalquilo C1-6, alquilo C1-6 sustituido con -NR14R15, alquilo C1-6 sustituido con -C(=O)-NR14R15, haloalquilo C1-6, hidroxialquilo C1-6, hidroxihaloalquilo C1-6, alcoxi C1-6, alcoxi C1-6-alquilo C1-6, en donde cada alquilo C1-6 puede estar opcionalmente sustituido con uno o dos grupos hidroxilo, R6, alquilo C1-6 sustituido con R6, -C(=O)-R6, -C(=O)-alquilo C1-6, -C(=O)-hidroxialquilo C1-6, -C(=O)-haloalquilo C1-6,-C(=O)- hidroxihaloalquilo C1-6, alquilo C1-6 sustituido con -Si(CH3)3, -S(=O)2-alquilo C1-6, -S(=O)2-haloalquilo C1-6, -S(=O)2-NR14R15, alquilo C1-6 sustituido con -S(=O)2-alquilo C1-6, alquilo C1-6 sustituido con -S(=O)2-haloalquilo C1-6, alquilo C1-6 sustituido con -S(=O)2-NR14R15, alquilo C1-6 sustituido con -NH-S(=O)2-alquilo C1-6, alquilo C1-6 sustituido con -NH-S(=O)2-haloalquilo C1-6 o alquilo C1-6 sustituido con -NH-S(=O)2-NR14R15; R12 representa hidrogeno o alquilo C1-4 opcionalmente sustituido con alcoxi C1-4; R13 representa cicloalquilo C3-8 o un heterociclilo monocíclico saturado de 4 a 6 miembros que contiene al menos un heteroátomo seleccionado de N, O o S, en donde dicho cicloalquilo C3-8 o heterociclilo monocíclico está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados cada uno, de modo independiente, de halogeno, hidroxilo, alquilo C1-6, -C(=O)-alquilo C1-6, alcoxi C1-6 o -NR14R15; R14 y R15 representan cada uno, de modo independiente, hidrogeno o haloalquilo C1-4 o alquilo C1-4 opcionalmente sustituido con un sustituy
ARP110101476 2010-04-30 2011-04-28 Derivados de quinoxalina AR080982A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32988410P 2010-04-30 2010-04-30
GB201007286A GB201007286D0 (en) 2010-04-30 2010-04-30 New compounds

Publications (1)

Publication Number Publication Date
AR080982A1 true AR080982A1 (es) 2012-05-23

Family

ID=42289929

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101476 AR080982A1 (es) 2010-04-30 2011-04-28 Derivados de quinoxalina

Country Status (41)

Country Link
US (6) US8895601B2 (es)
EP (3) EP3178818B1 (es)
JP (1) JP5639261B2 (es)
KR (2) KR101889565B1 (es)
CN (2) CN104725362B (es)
AP (1) AP3210A (es)
AR (1) AR080982A1 (es)
AU (2) AU2011247047B2 (es)
BR (1) BR112012027509B1 (es)
CA (1) CA2796204C (es)
CL (1) CL2012003048A1 (es)
CR (2) CR20180339A (es)
CY (2) CY1121882T1 (es)
DK (3) DK3590934T3 (es)
EA (2) EA023222B8 (es)
EC (1) ECSP12012318A (es)
ES (3) ES2899937T3 (es)
FI (1) FIC20250009I1 (es)
FR (1) FR25C1006I1 (es)
GB (1) GB201007286D0 (es)
HR (1) HRP20211675T1 (es)
HU (4) HUE033702T2 (es)
IL (1) IL222600A (es)
IN (1) IN2012MN02591A (es)
JO (1) JO3366B1 (es)
LT (4) LT2563775T (es)
ME (1) ME01825B (es)
MX (2) MX365702B (es)
MY (2) MY191669A (es)
NL (1) NL301318I2 (es)
NO (1) NO2025011I1 (es)
NZ (1) NZ602726A (es)
PH (1) PH12012501993A1 (es)
PL (3) PL3590934T3 (es)
PT (3) PT3178818T (es)
RS (3) RS55863B1 (es)
SG (2) SG10201708578QA (es)
SI (3) SI3178818T1 (es)
SM (3) SMT202100662T1 (es)
TW (1) TWI545122B (es)
WO (1) WO2011135376A1 (es)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2118074T1 (sl) 2007-02-01 2014-05-30 Resverlogix Corp. Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
BRPI1014956B8 (pt) 2009-04-22 2021-05-25 Resverlogix Corp agentes anti-inflamatórios
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) * 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
RU2019102203A (ru) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
DK2906531T3 (en) * 2012-10-15 2018-02-05 Resverlogix Corp APPLICABLE COMPOUNDS IN THE SYNTHESIS OF BENZAMIDE COMPOUNDS
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
AU2013337264B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP3939614A1 (en) 2013-01-18 2022-01-19 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
CN111793068A (zh) * 2013-03-15 2020-10-20 西建卡尔有限责任公司 杂芳基化合物和其用途
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
KR102350704B1 (ko) 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
GB201307577D0 (en) * 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
CN104163794A (zh) * 2013-10-17 2014-11-26 中国药科大学 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
HUE053653T2 (hu) * 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
ES3014202T3 (en) * 2014-03-26 2025-04-21 Astex Therapeutics Ltd Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors
JO3512B1 (ar) * 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
CN105017227B (zh) * 2014-07-08 2018-03-09 四川百利药业有限责任公司 N‑(1h‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物
US9951047B2 (en) 2014-08-18 2018-04-24 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
SMT202200177T1 (it) * 2014-09-26 2022-05-12 Janssen Pharmaceutica Nv Uso di gruppi di geni mutanti del fgfr nell'identificazione di pazienti affetti da cancro che saranno responsivi al trattamento con un inibitore del fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI695837B (zh) 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
EP3275442B1 (en) 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
TWI703984B (zh) * 2015-04-03 2020-09-11 英商阿斯特克斯治療有限公司 用於癌症治療之fgfr/pd-1組合療法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
RU2747644C2 (ru) * 2015-09-23 2021-05-11 Янссен Фармацевтика Нв Бигетероарил-замещенные 1,4-бензодиазепины и пути их применения для лечения рака
HRP20201157T1 (hr) * 2015-09-23 2020-11-13 Janssen Pharmaceutica N.V. Triciklički heterocikli za liječenje raka
CN105596330B (zh) * 2015-12-11 2018-10-16 深圳市坤健创新药物研究院 虚拟筛选化合物在制备激酶抑制剂中的应用和药物
WO2017104739A1 (ja) 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
BR112019007271A2 (pt) * 2016-10-10 2019-09-17 Dev Ct Biotechnology compostos de quinoxalina como inibidores do receptor da tirosina quinase do tipo iii
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
CN118638025A (zh) * 2017-08-21 2024-09-13 细胞基因公司 制备(s)-4,5-二氨基-5-氧代戊酸叔丁酯的工艺
US11661411B2 (en) 2017-12-01 2023-05-30 Board Of Regents Of The University Of Nebraska Quinoxaline compounds and uses thereof
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
JP7491510B2 (ja) * 2018-04-26 2024-05-28 メディシナル バイオコンバージェンス リサーチ センター ｍＴＯＲ阻害剤としての新規化合物及びその用途
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
US12133851B2 (en) 2018-09-21 2024-11-05 Janssen Pharmaceutica Nv Treatment of cholangiocarcinoma
WO2020131674A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020205493A1 (en) 2019-03-29 2020-10-08 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EP3946340A1 (en) 2019-03-29 2022-02-09 Janssen Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
WO2020208592A1 (en) * 2019-04-12 2020-10-15 Dr. Reddy’S Laboratories Limited Process for preparation of erdafitinib, its purification and amorphous solid dispersion
CN111909044A (zh) * 2019-05-09 2020-11-10 南京爱德程医药科技有限公司 2-(烷基氨基)乙基苯甲酸酯类化合物的合成方法
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI759829B (zh) * 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
AU2020352668A1 (en) 2019-09-26 2022-03-31 Janssen Pharmaceutica Nv Use of FGFR inhibitors in FGFR-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN110790677B (zh) * 2019-11-05 2022-04-29 浙江工业大学 一种金刚烷甲酰胺类化合物及其制备方法和应用
MX2022006370A (es) 2019-11-25 2022-09-07 Amgen Inc Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso.
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CN113024518A (zh) * 2019-12-09 2021-06-25 武汉九州钰民医药科技有限公司 一种厄达替尼的制备方法
CN113024517A (zh) * 2019-12-09 2021-06-25 武汉九州钰民医药科技有限公司 一种制备厄达替尼的方法
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114945367A (zh) * 2020-01-17 2022-08-26 贝达医药公司 作为fgfr激酶抑制剂的哒嗪和1,2,4-三嗪衍生物
AU2021220285A1 (en) 2020-02-12 2022-10-06 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
IL295515A (en) 2020-02-12 2022-10-01 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma
WO2022040111A2 (en) 2020-08-17 2022-02-24 Teva Pharmaceuticals International Gmbh Solid state forms of erdafitinib salts and processes for preparation of erdafitinib
CN112920167B (zh) * 2020-08-19 2022-08-26 四川大学华西医院 靶向fgfr和hdac的双靶点抑制剂及其制备方法和应用、药物组合物及药剂
KR20230069958A (ko) 2020-09-14 2023-05-19 얀센 파마슈티카 엔.브이. Fgfr 억제제 조합 요법
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
JP2024518612A (ja) 2021-05-19 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 進行性固形腫瘍の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
US20240382483A1 (en) 2021-06-22 2024-11-21 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
AU2022365014A1 (en) 2021-10-12 2024-05-30 Taris Biomedical Llc Erdafitinib formulations and systems for intravesical administration
JP2024540411A (ja) 2021-11-08 2024-10-31 プロジェントス・セラピューティクス・インコーポレイテッド 血小板由来成長因子受容体（ｐｄｇｆｒ）アルファ阻害剤及びその使用
EP4479055A1 (en) * 2022-02-18 2024-12-25 TARIS Biomedical LLC Erdafitinib formulations and osmotic systems for intravesical administration
CN115108926B (zh) * 2022-04-02 2023-06-20 上海工程技术大学 一种用于制备厄达替尼的中间体化合物及制备方法
CN120813357A (zh) 2023-02-13 2025-10-17 詹森药业有限公司 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂
CN120731076A (zh) 2023-02-13 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌
CN119101036A (zh) * 2023-06-08 2024-12-10 广州六顺生物科技有限公司 喹喔啉类化合物及其应用
WO2025059602A1 (en) 2023-09-14 2025-03-20 Taris Biomedical Llc Methods of treating bladder cancer using intravesical administration of erdafitinib
CN119350298A (zh) * 2024-10-09 2025-01-24 沈阳药科大学 一种厄达替尼的制备方法以及用于该方法的中间体化合物

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
GB9125001D0 (en) 1991-11-25 1992-01-22 Ici Plc Heterocyclic compounds
AU6909194A (en) 1993-05-14 1994-12-12 Board Of Regents, The University Of Texas System Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5882864A (en) 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
EP1001945B1 (en) 1997-05-28 2011-03-02 Aventis Pharmaceuticals Inc. QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
SK3542002A3 (en) 1999-09-15 2003-04-01 Warner Lambert Co Pteridinones as kinase inhibitors
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
ES2295441T3 (es) 2001-12-18 2008-04-16 MERCK & CO., INC. Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
SI1463506T1 (sl) 2001-12-24 2010-01-29 Astrazeneca Ab Substituirani kinazolinski derivati kot inhibitorji kinaz Aurora
JP2003213463A (ja) 2002-01-17 2003-07-30 Sumitomo Chem Co Ltd 金属腐食防止剤および洗浄液
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
US7074534B2 (en) 2002-07-10 2006-07-11 E. I. Du Pont De Nemours And Company Polymeric charge transport compositions and electronic devices made with such compositions
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
JP4560483B2 (ja) 2002-10-03 2010-10-13 ターゲジェン インコーポレーティッド 血管静態化物質およびそれらの使用法
AR043059A1 (es) 2002-11-12 2005-07-13 Bayer Pharmaceuticals Corp Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
DK1636228T3 (da) 2003-05-23 2009-02-23 Aeterna Zentaris Gmbh Nye pyridopyraziner og deres anvendelse som kinasemodulatorer
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
AU2004259000A1 (en) 2003-07-21 2005-02-03 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for PPAR
TW200517381A (en) 2003-08-01 2005-06-01 Genelabs Tech Inc Bicyclic heteroaryl derivatives
AU2004283479A1 (en) 2003-10-17 2005-05-06 4 Aza Bioscience Nv Heterocycle-substituted pteridine derivatives and their use in therapy
EP2762475A1 (en) 2003-11-07 2014-08-06 Novartis Vaccines and Diagnostics, Inc. Pharmaceutically acceptable salts of quinolinone compounds and their medical use
SG150533A1 (en) 2003-11-20 2009-03-30 Janssen Pharmaceutica Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
KR100861515B1 (ko) 2003-11-24 2008-10-02 에프. 호프만-라 로슈 아게 피라졸릴 및 이미다졸릴 피리미딘
AU2004303602C1 (en) * 2003-12-23 2009-05-28 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
BRPI0514691A (pt) 2004-08-31 2008-06-17 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
KR100875408B1 (ko) 2004-10-14 2008-12-23 에프. 호프만-라 로슈 아게 Ｃｄｋ1 항증식성 활성을 갖는 1,5-나프티리딘 아졸리디논
MX2007004480A (es) 2004-10-15 2007-05-08 Astrazeneca Ab Quinoxalinas como inhibidores b raf.
WO2006066361A1 (en) 2004-12-24 2006-06-29 The University Of Queensland Method of treatment or prophylaxis
AU2006212726C1 (en) 2005-02-14 2013-05-16 Bionomics Limited Novel tubulin polymerisation inhibitors
WO2006092430A1 (de) 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
JP2008540535A (ja) 2005-05-12 2008-11-20 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
CA2608362A1 (en) 2005-05-18 2006-11-23 Wyeth 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
WO2007023186A1 (en) 2005-08-26 2007-03-01 Laboratoires Serono S.A. Pyrazine derivatives and use as pi3k inhibitors
CA2628039A1 (en) 2005-11-11 2007-05-18 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
DK1966214T3 (en) 2005-12-21 2017-02-13 Janssen Pharmaceutica Nv TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
GB0609621D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
ATE549338T1 (de) 2006-05-24 2012-03-15 Boehringer Ingelheim Int Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
US20100016293A1 (en) 2006-07-03 2010-01-21 Rogier Adriaan Smits Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
CN101600714B (zh) 2006-11-10 2013-08-21 百时美施贵宝公司 吡咯并吡啶激酶抑制剂
JP2008127446A (ja) 2006-11-20 2008-06-05 Canon Inc １，５−ナフチリジン化合物及び有機発光素子
MX2009006466A (es) 2006-12-13 2009-06-26 Schering Corp Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
RU2009122670A (ru) 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
US20100216767A1 (en) 2006-12-22 2010-08-26 Mina Aikawa Quinazolines for pdk1 inhibition
HRP20150642T1 (hr) * 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
EP2150255A4 (en) * 2007-05-10 2011-10-05 Glaxosmithkline Llc CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
EP1990342A1 (en) 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
BRPI0813105A2 (pt) 2007-06-20 2015-08-04 Mitsubishi Tanabe Pharma Corp Derivado de sulfonamida de ácido malônico e uso faramacêutico do mesmo
WO2008155378A1 (en) 2007-06-21 2008-12-24 Janssen Pharmaceutica Nv Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
US20090263397A1 (en) 2007-07-06 2009-10-22 Buck Elizabeth A Combination anti-cancer therapy
CN101827848B (zh) 2007-08-08 2012-11-07 葛兰素史密丝克莱恩有限责任公司 作为IGF-1R抑制剂用于治疗癌症的2-[(2-{苯基氨基}-1H-吡咯并[2,3-d]嘧啶-4-基)氨基]苯甲酰胺衍生物
WO2009021083A1 (en) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
US20090054304A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2009064835A1 (en) * 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
US20110129456A1 (en) 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
BRPI0913031A2 (pt) 2008-05-23 2019-11-26 Novartis Ag derivados de quinolina e quinoxalinas como inibidores de proteína tirosina quinase, seus usos e processo de fabricação, bem como composições farmacêuticas e combinação que os compreende
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
JP5662346B2 (ja) 2009-01-21 2015-01-28 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ 新規二環式抗生物質
CA2750051A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
DK3517534T3 (da) 2009-06-12 2024-05-27 Abivax Forbindelser, der er anvendelige til behandling af cancer
BR112012004533B1 (pt) 2009-09-03 2021-11-09 Bioenergenix Composto, composição farmacêutica, e uso do composto
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
WO2011146591A1 (en) 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011149937A1 (en) 2010-05-24 2011-12-01 Intellikine, Inc. Heterocyclic compounds and uses thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
PT2670753T (pt) 2011-01-31 2017-01-10 Novartis Ag Novos derivados heterocíclicos
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CA2846574C (en) 2011-08-26 2020-07-07 Neupharma, Inc. Quinoxaline sulfonamide derivates for use as kinase inhibitors
CN115403531A (zh) 2011-09-14 2022-11-29 润新生物公司 作为激酶抑制剂的化学实体、组合物及方法
EP2757885B1 (en) 2011-09-21 2017-03-15 Neupharma, Inc. Certain chemical entites, compositions, and methods
WO2013052699A2 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
PT2771342T (pt) 2011-10-28 2016-08-17 Novartis Ag Derivados de purina e o seu uso no tratamento de doença
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
MX365214B (es) 2012-03-08 2019-05-27 Astellas Pharma Inc Nuevo producto de fusion de fgfr3.
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
EP3939614A1 (en) 2013-01-18 2022-01-19 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
HK1226058A1 (zh) 2013-08-02 2017-09-22 亚尼塔公司 单独地或与其它试剂联合地使用axl/cmet抑制剂治疗多种癌症的方法
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
JO3512B1 (ar) * 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
ES3014202T3 (en) 2014-03-26 2025-04-21 Astex Therapeutics Ltd Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US20160243228A1 (en) 2015-02-19 2016-08-25 Bioclin Therapeutics, Inc. Methods, compositions, and kits for treatment of cancer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
HUE033702T2 (en) 2017-12-28
SMT202100662T1 (it) 2022-01-10
BR112012027509B1 (pt) 2022-07-05
US20130072457A1 (en) 2013-03-21
TWI545122B (zh) 2016-08-11
KR101933843B1 (ko) 2018-12-28
PL3590934T3 (pl) 2022-02-07
DK3590934T3 (da) 2021-11-08
MX2012012414A (es) 2013-02-26
NO2025011I1 (no) 2025-02-17
PL3178818T3 (pl) 2019-11-29
SG10201708578QA (en) 2017-11-29
NZ602726A (en) 2014-05-30
LTPA2025509I1 (es) 2025-03-10
SG184966A1 (en) 2012-11-29
LT3590934T (lt) 2021-12-27
EA023222B8 (ru) 2017-04-28
KR101889565B1 (ko) 2018-08-17
JO3366B1 (ar) 2019-03-13
KR20180093134A (ko) 2018-08-20
SI2563775T1 (sl) 2017-05-31
EP2563775A1 (en) 2013-03-06
SMT201700193T1 (it) 2017-05-08
US9850228B2 (en) 2017-12-26
MY191669A (en) 2022-07-06
FIC20250009I1 (fi) 2025-02-18
LT3178818T (lt) 2019-08-12
US20150105368A1 (en) 2015-04-16
AP3210A (en) 2015-04-30
CY1121882T1 (el) 2020-10-14
MX365702B (es) 2019-06-11
HUE045893T2 (hu) 2020-01-28
ME01825B (me) 2014-12-20
HRP20211675T1 (hr) 2022-02-18
EP3178818A1 (en) 2017-06-14
RS62570B1 (sr) 2021-12-31
US10519137B2 (en) 2019-12-31
AP2012006490A0 (en) 2012-10-31
CL2012003048A1 (es) 2013-04-19
AU2011247047B2 (en) 2017-01-19
HUE056999T2 (hu) 2022-04-28
CN104725362A (zh) 2015-06-24
PL2563775T3 (pl) 2017-07-31
BR112012027509A2 (pt) 2017-08-08
EP2563775B1 (en) 2017-01-04
FR25C1006I1 (fr) 2025-04-04
MY189427A (en) 2022-02-11
KR20130108076A (ko) 2013-10-02
EP3590934A1 (en) 2020-01-08
PT3178818T (pt) 2019-09-05
EA023222B1 (ru) 2016-05-31
JP5639261B2 (ja) 2014-12-10
DK2563775T3 (en) 2017-03-27
CR20180339A (es) 2018-11-12
US20200131153A1 (en) 2020-04-30
DK3178818T3 (da) 2019-07-22
RS59196B1 (sr) 2019-10-31
CN104725362B (zh) 2017-04-12
EA201500278A1 (ru) 2015-09-30
GB201007286D0 (en) 2010-06-16
CY1124928T1 (el) 2023-01-05
EA201291143A1 (ru) 2013-05-30
US20180127397A1 (en) 2018-05-10
US9464071B2 (en) 2016-10-11
AU2017202512B2 (en) 2018-07-26
BR112012027509A8 (pt) 2021-11-03
US20220135544A1 (en) 2022-05-05
CN102858765A (zh) 2013-01-02
ES2899937T3 (es) 2022-03-15
CR20120576A (es) 2013-03-04
PH12012501993A1 (en) 2016-07-29
US8895601B2 (en) 2014-11-25
SI3590934T1 (sl) 2022-03-31
ES2742409T3 (es) 2020-02-14
EA028599B1 (ru) 2017-12-29
ECSP12012318A (es) 2013-02-28
EP3178818B1 (en) 2019-05-22
PT3590934T (pt) 2021-11-25
IN2012MN02591A (es) 2015-06-12
IL222600A (en) 2016-02-29
SMT201900469T1 (it) 2019-09-09
EP3590934B1 (en) 2021-08-25
AU2017202512A1 (en) 2017-05-04
US20160311800A1 (en) 2016-10-27
LT2563775T (lt) 2017-04-10
AU2011247047A1 (en) 2013-01-10
IL222600A0 (en) 2012-12-31
NL301318I2 (nl) 2025-03-13
WO2011135376A1 (en) 2011-11-03
SI3178818T1 (sl) 2019-09-30
RS55863B1 (sr) 2017-08-31
HUS2500011I1 (hu) 2025-03-28
CN102858765B (zh) 2015-04-01
JP2013528580A (ja) 2013-07-11
PT2563775T (pt) 2017-04-18
ES2621461T3 (es) 2017-07-04
TW201204714A (en) 2012-02-01
CA2796204A1 (en) 2011-11-03
CA2796204C (en) 2020-08-25

Similar Documents

Publication Publication Date Title
AR080982A1 (es) Derivados de quinoxalina
MX2015012815A (es) Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores de bromodominio.
GT200600398A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
AR100442A1 (es) Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
AR088567A1 (es) Derivados de piridopiridazina
CY1111281T1 (el) Παραγωγα πουρινης ως ανοσοτροποποιητες
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
CR20120302A (es) Derivados bencimidazol-imidazol
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
EA201690760A1 (ru) Производные карбоксамида и их применение в качестве медикаментов для лечения гепатита b
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
UA117246C2 (uk) Похідні сульфамоїлпіроламіду та їх застосування як медикаментів для лікування гепатиту в
EA201591890A1 (ru) Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
AR061643A1 (es) Derivados de ureas de piperidina o pirrolidina, metodos para su preparacion, una composicion farmaceutica que los comprende y el empleo de estos en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la enzima 11beta-hsd1.
MX375789B (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de hepatitis b.
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
NO20076460L (no) Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
BR112015026721A2 (pt) derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer
BR112014032581A2 (pt) inibidores de bifluorodioxalano-amino-benzimidazol qui-nase para o tratamento de câncer, distúrbios do snc e inflamação autoimune
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные

Legal Events

Date Code Title Description
FG Grant, registration